Plasma Lysophasphatidic Acid Level: A Diagnostic Tool and Benchmark for Ovarian Cancer Management
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 1, Issue 5
Abstract
In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphatidic acid (LPA), present in ascitic fluid, motivates the enlargement of malignant ovarian tumors by raising the appearance of vascular endothelial growth factor (VEGF) in ovarian cancer cells. Ovarian cancer cell progress is repressed by alendronate, a nitrogen containing biophosphate which attenuate the establishment of Rho by blocking the mevalonate pathway. In ovarian cancer there is formation of tumor cells in ovarian tissues. In the US, in about 69 women 1 woman will build up this malignancy during her life span. And, not only this disease occurs in women over the age of 50 but also in women with younger ages [1]. There are many different types of ovarian tumors. Few of them comprise: Ovarian (it is mainly extensive type of ovarian tumor), Ovarian germ cell tumor and Low malignant potential ovarian tumor [2]. Plasma LPA levels may demonstrate that it is a potential biomarker for ovarian cancer and other gynecologic cancers [3]. Significantly high total LPA levels were resolute in the sera of patients with diverse types of tumors benevolent (benign) and wicked (malignant) [4]. Lysophosphatidic acid (LPA), lysophosphatidylinositol (LPI), lysophosphatidylcholine (LPC), and sphingosine-1-phosphate (S1P) appear useful as investigative and predictive biomarkers of ovarian cancer [5].
Authors and Affiliations
Muhammad Imran Qadir, Saima Saadat
Keywords
Related Articles
- EP ID EP587867
- DOI 10.32474/OAJOM.2018.01.000122
- Views 61
- Downloads 0
Metformin Treatment Represses Vascular Endothelial Growth Factor Gene Transcription in MCF-7 Breast Cancer Cells
Background/Aim:Targeting angiogenesis preferentially in cancer is a promising approach to improve treatment efficacy and safety. The aim of this study is investigate potential upregulation of Krüppel like factor-4(KLF-4)...
Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)
Checkpoint inhibitors have demonstrated efficacy in squamous NSCLC with tolerable toxicity profile. They are used as a monotherapy, in combination with chemotherapy or following chemo-radiotherapy as a first line, second...
Acute Erythroblastic Leukemia Revealed by Dermatological Manifestations
Acute erythroblastic leukemia is characterized by the proliferation of a predominant erythrocyte population on other lineages. Cutaneous manifestations remain rare and misleading, making the diagnosis of difficult to sus...
Percutaneous nephrostomy in the management of malignant ureteral obstruction: an alternative using central venous catheter and “zero irradiation”
Introduction and Objective: Percutaneous Nephrostomy (NP) is a procedure that involves the placement of a drainage catheter in the renal pelvis by puncture through the skin guided by an imaging method. The objective of t...
A Modern and Comprehensive Experimental Biospectroscopic Comparative Study on Human Common Cancers' Cells, Tissues and Tumors before and after Synchrotron Radiation Therapy
In the current study, we have experimentally and comparatively investigated and compared malignant human common cancers' cells, tissues and tumors such as Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Endometri...